Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Roche’s VEGFxAng2 bispecific antibody faricimab has matched Regeneron’s blockbuster Eylea in two phase 3 diabetic macular edema clinical trials. Faricimab was non-inferior to Eylea despite people on the experimental drug transitioning to a 16-week dosing window during the study.